A5059729383- T-cell and Retrovirus Studies
- Vector-Borne Animal Diseases
- Animal Disease Management and Epidemiology
- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Eosinophilic Disorders and Syndromes
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Acute Lymphoblastic Leukemia research
- Cancer-related gene regulation
- Chronic Myeloid Leukemia Treatments
- Vasculitis and related conditions
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Galectins and Cancer Biology
- Brain Metastases and Treatment
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hepatitis C virus research
- Frailty in Older Adults
- Influenza Virus Research Studies
- Hereditary Neurological Disorders
- Amyloidosis: Diagnosis, Treatment, Outcomes
Sasebo City General Hospital
2021-2025
University of Tokyo Hospital
2018-2024
The University of Tokyo
2018-2021
Nagasaki Medical Center
2009-2021
Centro de Investigación del Cáncer
2019
Universidad de Salamanca
2019
Nagasaki University
2013-2014
Epigenomes enable the rectification of disordered cancer gene expression, thereby providing new targets for pharmacological interventions. The clinical utility targeting histone H3 lysine trimethylation (H3K27me3) as an epigenetic hallmark has been demonstrated
Abstract Subclonal genetic heterogeneity and their diverse gene expression impose serious problems in understanding the behavior of cancers contemplating therapeutic strategies. Here we develop utilize a capture-based sequencing panel, which covers host hotspot genes full-length genome human T-cell leukemia virus type-1 (HTLV-1), to investigate clonal architecture adult leukemia-lymphoma (ATL). For chronologically collected specimens from patients with ATL or pre-onset individuals, integrate...
The characteristics of adult patients with chronic active Epstein-Barr virus infection are poorly recognized, hindering early diagnosis and an improved prognosis. We studied 54 adult-onset diagnosed between 2005 2015. Adult onset was defined as estimated age 15 years or older. To characterize the clinical features these adults, we compared them to those 75 pediatric cases (estimated
Human T cell leukemia virus 1 (HTLV-1) causes the functionally debilitating disease HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP) as well adult lymphoma (ATLL). Although there were concerns that mortality of HAM/TSP could be affected by development ATLL, prospective evidence was lacking in this area. In 5-y cohort study, we determined mortality, prevalence, and incidence ATLL 527 patients. The standard ratio patients 2.25, one major death (5/33 deaths). prevalence these...
ABSTRACT CD5‐positive diffuse large B‐cell lymphoma (CD5+ DLBCL) is characterized by a poor prognosis and frequent central nervous system (CNS) relapse. Sandwich therapy comprising dose‐adjusted (DA)‐EPOCH‐R (etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, rituximab) high‐dose methotrexate (HD‐MTX) (DA‐EPOCH‐R/HD‐MTX) showed excellent efficacy manageable safety in phase II study of patients diagnosed with stage II–IV CD5+ DLBCL. To validate the results that elucidate...
The indolent adult T-cell leukemia-lymphoma prognostic index (iATL-PI) uses soluble interleukin-2 receptor (sIL-2R) levels of 1,000 and 6,000 U/mL as a cut-off. disadvantage the iATL-PI is that approximately half patients are classified intermediate risk (1,000 ≤ sIL-2R < 6,000). Here, we aimed to develop novel model for ATL using prospectively registered database. We identified 375 with ATL. Median age was 61 years. median follow-up surviving 62 months. In multivariate analysis overall...
Adult T cell leukemia/lymphoma (ATL) is a highly aggressive hematologic malignancy with very poor prognosis, and most patients ATL are elderly. Although post-transplantation cyclophosphamide (PTCy) has yielded promising results in various diseases, available data limited regarding its outcomes ATL. The aim of this study was to determine the safety efficacy reduced-intensity peripheral blood stem transplantation (PBSCT) from human leukocyte antigen (HLA)-haploidentical donor using PTCy as...
Abstract We recently took advantage of the universal expression cell adhesion molecule 1 (CADM1) by CD4 + cells infected with HTLV‐1 and downregulation CD7 that corresponds oncogenic stage HTLV‐1‐infected to develop a flow cytometric system using CADM1 versus plotting cells. risk‐stratified asymptomatic carriers (AC) indolent adult T‐cell leukemia/lymphoma (ATL) cases based on percentage, in which clones are efficiently enriched. AC ATL were initially classified according their percentage....
Abstract Aggressive adult T-cell leukemia/lymphoma (ATL) is a hematological malignancy that difficult to treat with chemotherapy alone, and allogeneic hematopoietic cell transplantation (allo-HCT) potentially curative therapy. We conducted multicenter, prospective, observational study clarify the treatment outcomes of aggressive ATL in current era. Between 2015 2018, 113 patients aged 70 years or younger newly diagnosed were enrolled. The median age at diagnosis was 61 years. Treatment...
7001 Background: Aggressive adult T-cell leukemia-lymphoma (ATL) (i.e., acute, lymphoma and unfavorable chronic types) has poor prognosis with around a 1-year median survival time (MST) chemotherapy. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) provides durable response 3-year overall (3-y OS) of 40%. However, the results were mostly from retrospective studies. This single-arm, phase 3 trial by Japan Clinical Oncology Group (JCOG) evaluated upfront allo-HSCT for aggressive...
Patients with adult T-cell leukemia (ATL) exhibit a poor prognosis and overall survival rate when treated standard chemotherapy, highlighting the continued requirement for development of novel safe effective therapies human virus type 1 (HTLV-1)-related diseases. In this study, we demonstrated that MK-2048, second-generation HIV-1 integrase (IN) inhibitor, potently selectively kills HTLV-1-infected cells. Differential transcriptome profiling revealed significantly elevated levels gene...